Among these four subgroups, HCC patients with high CASC2 expression and low miR-367 expression had the best prognosis, while CASC2 low-expressing and miR-367 high-expressing HCC patients showed the poorest prognosis (Fig. 8c). This evidence concerns the gene CASC2 and hepatocellular carcinoma.